|I||A||In patients with SIHD treated with DAPT after BMS implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for a minimum of 1 month (94,95).|
|I||B-R SR||In patients with SIHD treated with DAPT after DES implantation, P2Y12 inhibitor therapy (clopidogrel) should be given for at least 6 months (17,18,21,30,96,97).|
|I||B-NR||In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended (56–60,75–78).|
|IIb||A SR||In patients with SIHD treated with DAPT after BMS or DES implantation who have tolerated DAPT without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use), continuation of DAPT with clopidogrel for longer than 1 month in patients treated with BMS or longer than 6 months in patients treated with DES may be reasonable (16,22,24–26,30,50).|
|IIb||C-LD||In patients with SIHD treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery), or develop significant overt bleeding, discontinuation of P2Y12 inhibitor therapy after 3 months may be reasonable (19,20,34,36,37).|
SR indicates systematic review.